Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | LPL | P06858 | 1/20 | 0.43 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.31 |
| ▸ | F2 | P00734 | 1/20 | 0.31 |
| ▸ | F10 | P00742 | 1/20 | 0.31 |
| ▸ | F11 | P03951 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.30 |
| ▸ | IDO1 | P14902 | 1/20 | 0.30 |
| ▸ | TDO2 | P48775 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489214 | 1.00 | FFAR1 (0.44) | FFAR1LPLLIPGESR2F2 | |
| SCHEMBL31489648 | 0.92 | LPL (0.43) | FFAR1LPLLIPGESR2F2 | |
| SCHEMBL31489362 | 0.92 | LPL (0.43) | FFAR1LPLLIPGESR2F2 | |
| SCHEMBL15653015 | 0.83 | LPL (0.47) | FFAR1LPLLIPGESR2CXCR2 | |
| SCHEMBL31489511 | 0.83 | LPL (0.47) | FFAR1LPLLIPGESR2CXCR2 | |
| SCHEMBL31489793 | 0.81 | FFAR1 (0.43) | FFAR1LPLLIPGESR2CXCR2 | |
| SCHEMBL22558697 | 0.81 | LPL (0.44) | FFAR1LPLLIPGESR2CXCR2 | |
| SCHEMBL31489712 | 0.80 | LPL (0.43) | FFAR1LPLLIPGESR2CXCR2 | |
| SCHEMBL22585809 | 0.80 | LPL (0.43) | FFAR1LPLLIPGESR2CXCR2 | |
| SCHEMBL31489271 | 0.80 | LPL (0.43) | FFAR1LPLLIPGESR2CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |